Georgia Roane, MD
Rheumatology · Charleston, SCNPI 1184662660
Payments from drug & device makers
Across 413 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- Pfizer$2K
- Amgen$1K
- AbbVie$1K
- Johnson & Johnson$775
- Lilly USA, LLC$524
- plus $4K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 1 | $2,198 |
| Pfizer | 29 | $1,653 |
| Amgen(2 entities) | 79 | $1,293 |
| AbbVie | 69 | $1,178 |
| Johnson & Johnson(2 entities) | 45 | $775 |
| Lilly USA, LLC | 25 | $524 |
| E.r. Squibb & Sons, L.L.C. | 22 | $418 |
| UCB, Inc. | 19 | $374 |
| AstraZeneca(2 entities) | 16 | $350 |
| Novartis | 14 | $340 |
| GSK | 20 | $336 |
| Aurinia Pharma U.S., Inc. | 9 | $237 |
| Radius Health, Inc. | 6 | $229 |
| Organon | 6 | $159 |
| Genentech USA, Inc. | 8 | $137 |
| Fresenius Kabi USA, LLC | 6 | $132 |
| Boehringer Ingelheim | 6 | $119 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $94 |
| Sanofi | 3 | $94 |
| Sandoz | 4 | $87 |
| Regeneron Healthcare Solutions, Inc. | 3 | $75 |
| Hikma Pharmaceuticals USA | 4 | $71 |
| Sobi, Inc | 2 | $64 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| Merck | 3 | $45 |
| Bristol Myers Squibb | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $32 |
| Bioventus LLC | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $26 |
| US Oncology Corporate, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
How this compares
$11,230 in reported general payments places this provider in the 65th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Charleston
- Richard SilverCharleston$1.6M
- James OatesCharleston$224K
- Gary GilkesonCharleston$67K
- Melissa CunninghamCharleston$60K
- Eric ZollarsCharleston$47K
- Deanna Baker FrostCharleston$43K
- Diane KamenCharleston$32K
- Erica AndersonCharleston$6K
- Clarence LegertonSummerville$7.7M
- Gary FinkSummerville$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.